Toggle navigation
ABOUT US
ABOUT US
WHY IJISRT
MISSION & SCOPE
EDITORIAL BOARD
PAPER PUBLISHING
INDEXING
PROCESSING CHARGES
PROCESSING CHARGES
CALL FOR PAPERS
UPCOMING ISSUE
PUBLISHING ETHICS
RESEARCH PAPER
TOPICS
FOR AUTHORS
FOR AUTHORS
SUBMIT PAPER FOR PUBLICATION
PROCESSING CHARGES
APPLY FOR CERTIFICATE HARDCOPY
AUTHOR GUIDELINES
DOWNLOAD
IJISRT Video
SPECIAL ISSUE
MMK:ACE-2023
2nd ICTSA-2022
MMK : ACE - 2021
MMK: ACE - 2019
AAM – 2019
BROWSE ARCHIVE
Volume 9 - 2024
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 8 - 2023
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 7 - 2022
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 6 - 2021
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 5 - 2020
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 4 - 2019
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 3 - 2018
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 2 - 2017
Issue 12 - December
Issue 11 - November
Issue 10 - October
Issue 9 - September
Issue 8 - August
Issue 7 - July
Issue 6 - June
Issue 5 - May
Issue 4 - April
Issue 3 - March
Issue 2 - February
Issue 1 - January
Volume 1 - 2016
Issue 9 - December
Issue 8 - November
Issue 7 - October
Issue 6 - September
Issue 5 - August
Issue 4 - July
Issue 3 - June
Issue 2 - May
Issue 1 April
PEER REVIEWS
PEER REVIEWS
JOIN AS REVIEWER
GUIDE TO REVIEWING
CONTACT US
SIGN UP
LOGIN
×
Subscribe Now
Subscribe Newsletter For Latest Updates
Cite Paper
Authors
Apply For Certificate Hard Copy
Volume
9
, Issue
4
, April
–
2024
International Journal of Innovative Science and Research Technology
ISSN No:
-
2456
-
2165
https://doi.org/10.38124/ijisrt/IJISRT24APR2251
IJISRT24APR2251
www.ijisrt.com
1179
Implications of Adnexal Invasions in
Primary Extramammary Paget
’
s
Disease
:
A
Systematic
Review
Dr. Sabita Aryal
1
; Dr. Liu Ye Qiang
2
,*
Shanghai Skin Disease Hospital, School of
Medicine,
Tongji University, No. 1278 Baode
Road,
Shanghai, 200443,
China
Corresponding Author:
-
Dr. Liu Ye Qiang
2,*
Abstract
:
-
Extramammary Paget
’
s disease (EMPD) is a
n
erratic
malignant skin disorder primarily affecting
skin
areas
abundant with skin appendages
like
hair follicles
.
The vulva is most
involved site
, followed by
genital areas
,
penoscrotal
regions
and axillary skin
. EMPD presents as
erythematous skin lesions resembling eczema, typically
progressing slowly
,
either p
rimary or secondary
manifestations. Primary EMPD originates as an
intraepithelial neoplasm of the epidermis, often leading
to local lymph node metastases and distant metastases. A
systematic literature search using targeted keywords
across multiple databas
es was conducted. Studies
focusing on EMPD, adnexal involvement, depth,
recurrence, and prognosis were included by keeping in
view the objective which is to determine the significance
of adnexal involvement and depth concerning recurrence
and prognosis in
the primary EMPD. Adnexal
involvement, especially in hair follicles and eccrine duc
ts
,
is prevalent in primary EMPD. However, its correlation
with tumor progression or recurrence rates remains
inconclusive. Surgical excision, including Mohs
micrographic su
rgery, is the primary therapeutic
approach, with topical agents and systemic treatments
used in advanced cases. Future studies regarding
understanding adnexal involvement's depth and
significance are essential in designing effective targeted
therapeutic ap
proaches in EMPD.
Keywords:
-
Disease of the Cutaneous Annexes, Primary
EMPD, Extramammary Paget
’
s Disease, Skin Neoplasm,
Prognosis, Skin Adnexa, Adnexal Involvement.
I.
INTRODUCTION
First reported by Crocker in 1889,
EMPD
is a rare
malignant skin disorder that affects apocrine
rich
skin
sites
with an abundance of hair follicles.
[1, 2]
The vulva is the
most often occurring site; perineal, perianal, scrotal, and
penile skin are next in frequency. The axilla, buttocks,
thigh
s, eyelids, and external auditory canal are additional,
less common locations. Typically, erythematous or persistent
skin lesions resembling eczema are the first sign of EMPD.
[3]
Another name for EMPD is skin in situ adenocarcinoma.
The tumor is limited t
o the epidermis, grows slowly, and
rarely spreads to other areas of the body. There are two types
of EMPD manifestations: primary and secondary. Secondary
EMPD
involves
the direct extension of an underlying
internal neoplasm or the epidermotropic spread of
malignant
cells, whereas primary EMPD originates as an intraepithelial
neoplasm of the epidermis
[4]
, while some theory
suggesting
infiltration via
adnexal
structures
(Figure 1).
Predominant
cases of EMPD are identified as carcinoma
I
n
S
itu
, which typically progresses slowly. However, local
lymph node (LN) metastases and
non
-
local
metastases often
occur once Paget cells penetrate deeply into the dermis
[5]
.
Due to the limited effectiveness of conventional
chemotherapies, which are typically
used to treat EMPD,
cases with distant metastases
with multiple lesions
have a
poor prognosis. Here, we review EMPD, covering its
diagnosis, pathogenesis, and treatment, with an emphasis on
recent developments.
Fig 1
Adnexal
Proliferation
in
Primary
EMP
D
Showing
Pagetoid
Cells Infiltrating
the
Dermal Layer
via
Adnexal Structures
Volume
9
, Issue
4
, April
–
2024
International Journal of Innovative Science and Research Technology
ISSN No:
-
2456
-
2165
https://doi.org/10.38124/ijisrt/IJISRT24APR2251
IJISRT24APR2251
www.ijisrt.com
1180
II.
MATERIALS AND METHODOLOGY
A.
Study Design
Research Question
:
The primary research question
driving
this systematic
review is: "What is the significance of adnexal involvement
and depth concerning recurrence and prognosis in primary
extramammary Paget's disease (EMPD)?"
Statement of Aims
:
This systematic review aims to comprehensively
evaluate the significance of adnexal involvement and depth
in primary extramammary Paget's disease (EMPD)
concerning recurrence and prognosis.
The review aims to
consolidate existing research to investigate th
e role and
depth of adnexal structures in primary EMPD, and how they
correlate with tumor progression, recurrence rates, survival
rates, and overall patient prognosis.
Search Strategy:
The literature search methodology involved systematic
techniques util
izing targeted keywords across several
databases, including PubMed, Google Scholar, ProQuest,
ScienceDirect, and the university's linked library databases
such as ISI Web of Science. The search strategy
incorporated a blend of MeSH terms and keywords focus
ing
on extramammary Paget disease, Paget, adnexal
involvement, depth, recurrence, and prognosis by keeping in
view the study's objective.
Moreover, a manual search is performed for relevant
articles in the journal's bibliography list and included
studies.
Unpublished studies/gray literature are manually
searched in Google Scholar and gray literature databases
using study keywords.
This review
follow
s
PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta
-
analyses) guidelines.
B.
Study Selection Pr
ocess
The first step was identifying and retrieving articles
based on inclusion and exclusion criteria
(shown in Figure
2
)
.
Inclusion Criteria
Studies focused on primary extramammary
Paget's
disease (EMPD), including its diagnosis, pathogenesis,
treatment, and outcomes related to adnexal involvement
and depth.
English
-
language publications were included to ensure
comprehensive understanding and analysis.
Studies reporting outcomes rel
ated to adnexal
involvement and depth concerning recurrence rates,
prognosis, therapeutic approaches, and advancements in
EMPD management.
Exclusion Criteria
Studies published in languages other than English were
excluded due to potential limitations
in comprehension
and analysis.
Literature lacking empirical evidence, including
conceptual papers, reviews lacking original research,
case reports, case series, conference abstracts, or
theoretical discussions without practical implications,
were excluded
.
Studies not specifically detailing adnexal involvement
and depth in primary EMPD or not directly related to the
research questions were excluded.
Fig
2 PRISMA
Flow Chart Showing
the
Selection
of
Included Studies
III.
RESULTS
The initial search identified a total of 289 citations, 94
of which were duplicated. Total articles retrieved after
removing duplication is 195. The next step of the process
involved reading the abstracts in more detail and narrowing
down the larger set of
articles to those that specifically
addressed adnexal involvement in extramammary Paget
disease. Title and abstract screening of the remaining 195
citations resulted in the inclusion of 67 citations for further
review. After examination of full
-
text artic
les, 9 articles
were identified as being eligible.
Volume
9
, Issue
4
, April
–
2024
International Journal of Innovative Science and Research Technology
ISSN No:
-
2456
-
2165
https://doi.org/10.38124/ijisrt/IJISRT24APR2251
IJISRT24APR2251
www.ijisrt.com
1181
IV.
DISCUSSION
Intraepidermal adenocarcinomas are the term used to
describe both extramammary and mammary Paget disease.
EMPD is more frequently a primary intraepidermal lesion
than mammary Paget's disease;
only 20% of cases show
evidence of a dermal invasive component.
[6]
A disease is
deemed minimally invasive if the invasive component is less
than 1.0 mm in depth, and full excision is typically curative.
[7]
An underlying cutaneous adnexal carcinoma, typic
ally an
apocrine adenocarcinoma, may also be linked to EMPD. Up
to 30% of cases indicate the spread of metastatic cancer
from a regional visceral malignancy, such as rectal, cervical,
prostate, or transitional cell carcinoma. In these cases, the
tumor cell
s show positive profiles for CK 7 and potentially
GCDFP
-
15, but they also exhibit immunohistochemical
profiles that are similar to the original carcinoma, such as
positive for prostate
-
specific antigen in prostate cancer or
CK 20 or CA19.9 in genitourinary
or gastrointestinal
carcinomas.
[8]
Crude prevalence of EMPD in mainland
China was estimated to be 0.4 per 100,000 people in a recent
study by Yin et al. With
the
peak incidence
at
66 years
during first
diagnosis, the majority of people are between 50
and
80 years old.
[9]
Ghazawi et al. report that the vulva in females and the
scrotum and penis in males are the primary sites of EMPD
development, though perianal, axillar, or umbilicus regions
may also occasionally be affected
[10]
. Multifocal EPMD is
possible, and instances of double, triple, or synchronous
EMPD
—
EMPD that developed in more than two apocrine
gland
-
bearing areas
—
have also been documented.
[11]
There have also been cases reported where
hypopigmentation was the primary clinical presentatio
n;
these cases are challenging to diagnose as EMPD.
[12]
There may also be crust, scale, or erosion on the
erythematous lesions. These lesions can resemble several
different skin conditions, including psoriasis, eczema, and
fungal infections. Deep ulcers o
r nodules may appear in the
later stages. 10% of patients with EMPD are asymptomatic,
despite the possibility of developing related symptoms like
pruritus and tenderness.
[13]
The dermoscopic
characteristics of EMPD lesions have also been studied
recently.
[14]
Mun et al. compared the dermoscopic
characteristics of EMPD lesions with those of other skin
lesions, such as eczema, fungal infection, and Bowen
disease, the gross findings such as milky
-
red areas, dotted
vessels, glomerular vessels, polymorphous ve
ssels, surface
scales, and linear irregular vessels may be comparable to
EMPD.
[15]
Although the histogenesis of EPD is still unknown,
several theories point to pluripotent epidermal stem cells,
intraepidermal "Toker cells," apocrine glands, or both as
po
ssible sources. Mucin core proteins, androgen receptors,
Her
-
2 neu, gross cystic disease fluid protein
-
15, and
intermediate filaments of the cytokeratin (CK) type15
—
specifically, CK7 and CK20
—
are all expressed by Paget
cells.
[16]
Progeny from follicular s
tem cells can
differentiate into sebocytes, sweat glands, epidermis, and
hair follicle lineages. The bulge region's follicular stem cells
are distinguished by the expression of CK15 and CK19.
Both CK15 and CK19 are thought to be indicators of
derivation fr
om follicular stem cells of the upper hair follicle
and are expressed in trichogenic tumors.
[17]
A follicular
origin of Paget cells is further supported by CK20 positivity
in EPD without associated rectal carcinoma, as the hair
follicle stem cell niche is
co
-
occupied by CK20+ Merkel
cells and pluripotent neuroendocrine stem cells.
[18]
Furthermore, Tanaka et al. found that HER2 overexpression
and ERBB2 gene amplification did not differ between
primary lesions and lymph node (LN) metastasis in about
90% of
EMPD patients, suggesting that HER2 targeting
therapies could be useful for treating both primary and
metastatic lesions.
[19]
The relationship between adnexal involvement and
tumor progression has not been thoroughly studied, even
though it was a common
finding in the Shaco
-
Levy et al.
report and did not impact the recurrence rate. In a study,
comedone necrosis was found in 6 cases (11.3%) and
adnexal involvement in 46 cases (86.7%). There was no
statistically significant difference in the percentage of c
ases
with adnexal involvement displaying a score of 2 between
invasive EMPD (77.8%) and in situ EMPD (57.7%). These
findings imply that comedon necrosis and the extent of
adnexal involvement are not linked to the progression of
EMPD.
[20]
Preti et al. exam
ined 122 patients with vulvar
primary
EMPD and found that, for intraepithelial and
microinvasive
(≤ 1
mm) vulvar
primary
EMPD, the cancer
-
specific survival at 120 months was 100%, while for
invasive (>1 mm) vulvar
primary
EMPD, it was 31%.
[21]
Similar to
this, van der Linden et al. examined 113 patients
with vulvar
primary
EMPD and found that while the 5
-
year
disease
-
specific survival rate was only 50% and
significantly worse in invasive
primary
EMPD, it was more
than 98% in noninvasive and micro
-
invasive
EMPD. Thus,
microinvasion might not have a major impact on EMPD
patients' prognosis.
[22]
In 1993, the Japanese Skin Cancer Society proposed a
TNM staging system preliminary for
primary
EMPD. This
system classified the primary tumor category based on
lymp
hovascular invasion depth, the lymph node category
based on metastasis site (unilateral or bilateral inguinal
nodes), and the term "distant metastasis" was defined as
metastasis in a lymph node that was outside of the regional
lymphatic basin or in a dista
nt organ. This staging system
was used in a cohort study by Hatta et al., who demonstrated
its usefulness with 76 patients.
[23]
Regarding the
prognostic factors associated with
primary
EMPD, Ito et al.
retrospectively analyzed 35 patients and found that t
he
degree of tumor invasion, lymph node metastases, clinically
palpable lymph nodes, and the presence of a nodule on the
primary lesion were significant prognostic factors.
[24
-
26]
A
recent study found that while invasion level and perianal
location were n
ot significantly associated with a worse
prognosis, tumor thickness, and lymphovascular invasion
were. In terms of node status, it was discovered that patients
who had two or more node metastases fared worse in terms
of survival than those who only had one
. Metastatic lymph
Volume
9
, Issue
4
, April
–
2024
International Journal of Innovative Science and Research Technology
ISSN No:
-
2456
-
2165
https://doi.org/10.38124/ijisrt/IJISRT24APR2251
IJISRT24APR2251
www.ijisrt.com
1182
node distribution on both sides did not significantly affect
prognosis.
[5]
According to conventional wisdom, Paget's disease is a
form of skin in
-
situ adenocarcinoma. Because EMPD
progresses slowly and typically affects only the
epidermis
and cutaneous adnexal structures, most patients have a good
prognosis.
[27]
The adnexa may act as a conduit for
carcinoma to spread to deeper tissues where local
therapeutic agents are less likely to be effective, as
evidenced by earlier case rep
orts and case series.
[28
-
30]
According to a study, adnexal involvement is a highly
prevalent feature in over 90% of cases of primary EMPD.
The most often affected anatomical structures by Paget cells
are hair follicles and eccrine ducts. The most profound
involvement in this investigation was 3.6 mm, and the
median for each adnexal structure was between 0.93 mm
(eccrine ducts) and 2.55 mm (eccrine secretory coils).
[31]
Future development of new local treatment modalities
or planning of topical nonsurgical treatment should consider
this information. Imiquimod, 5
-
fluorouracil, and retinoic
acid are currently used to treat
primary
EMPD to replace
more invasive, frequently d
isfiguring surgical methods.
Additional cutting
-
edge therapies under investigation
include photodynamic therapy, trastuzumab, either alone or
in conjunction with chemotherapy, and CO2 laser.
[32, 33]
Although the aforementioned treatment modalities have
di
fferent mechanisms of action, understanding the depths of
tumor deposits and the depth of skin penetration are
undoubtedly crucial for designing an effective treatment
plan. While 5
-
fluorouracil is said to penetrate the skin to a
depth of 1
-
2 mm, we were u
nable to ascertain the potential
depth of imiquimod's skin penetration based on our review
of the literature.
[34]
The principal therapeutic approach entails a broad local
surgical excision of the affected area. In comparison to the
standard treatment (w
ide local excision), Mohs
micrographic surgery resulted in an over 10
-
fold reduction
in the risk of positive margins.
[35]
A study by Long et al.
with 154 cases of EMPD found that females were more
likely than males to have a positive margin. They also
con
cluded that patients with positive pathologic margins had
a 3.5
-
fold higher chance of recurrence than patients with
negative margins.
[36]
A study conducted between 1998 and
2012 by Fujisawa et al. with 151 patients examined the
function of sentinel lymph
node biopsy in EMPD. 107
patients in this cohort did not exhibit any clinically
noticeable lymphadenopathy, and all of them had sentinel
biopsies performed. Finally, it was discovered that 15% of
these clinically negative patients had lymph node
metastases
. This was linked to the primary specimen's
lymphovascular and deeper levels of invasion. This indicates
that, in the absence of clinically noticeable
lymphadenopathy, patients with invasive disease should
seek sentinel lymph node biopsy. Hence, patients w
ith early
-
stage lymph node metastases may have a better prognosis if
they receive early detection and lymph node dissection.
[5]
The 5
-
year overall survival rate for metastatic disease
is less than 10%. For these patients, there isn't yet a standard
syste
mic treatment plan.
[37, 38]
5
-
FU and cisplatin (FP
therapy), 5
-
FU, epirubicin, carboplatin, vincristine, and
mitomycin C (FECOM therapy), cisplatin, epirubicin, and
paclitaxel (PET therapy), or combination S
-
1 (tegafur, 5
-
FU,
and 5
-
chloro
-
2
-
4
-
dihydroxypyr
idine) and docetaxel, S
-
1
monotherapy, or docetaxel monotherapy are among the
available combination therapies.
[39]
Patients on FP and
FECOM regimens have shown a median progression
-
free
survival of 5.2 months and 6.5 months, respectively, even
though the
overall median survival is less than a year.
[40]
Future directions in the field of primary EMPD with
adnexal involvement hold immense promise for advancing
diagnosis, treatment, and patient outcomes. One critical area
of focus is the development of targe
ted therapies that
specifically address the mechanisms underlying adnexal
infiltration and disease progression. This includes
investigating molecular markers associated with adnexal
involvement, such as cell adhesion molecules, growth
factors, and signalin
g pathways implicated in tumor cell
survival and proliferation within adnexal structures. By
elucidating these molecular mechanisms, researchers can
identify potential therapeutic targets for novel drug
development. In addition to molecular and
microenviro
nmental studies, future diagnostic modalities
should aim for greater precision in detecting adnexal
involvement in
primary
EMPD. Advanced imaging
techniques, such as high
-
resolution MRI and molecular
imaging approaches, could enhance our ability to visuali
ze
tumor extent and accurately assess adnexal infiltration.
Integration of imaging data with histopathological findings
and biomarker analysis may enable more personalized
treatment strategies tailored to individual patients based on
the degree of adnexal
involvement and disease
aggressiveness.
V.
CONCLUSION
The prognosis and recurrence of primary EMPD are
closely
linked
with the extent of adnexal involvement. Over
90% of
primary
EMPD cases exhibit
adnexal
involvement
,
predominantly
in
hair follicles and
eccrine ducts. Although
this involvement has not been definitively linked to tumor
progression or higher recurrence rates, it plays a crucial role
by potentially facilitating deeper tissue infiltration, thus
highlighting its clinical importance.
Therapeut
ic options for primary EMPD range from
topical treatments like imiquimod and 5
-
fluorouracil to
surgical excision. Among surgical methods, Mohs
micrographic surgery is preferred for its enhanced margin
control. The efficacy of topical agents depends signifi
cantly
on the depth of Paget cell invasion within these adnexal
structures, illustrating the need to thoroughly understand the
pattern and extent of this invasion to optimize patient
management strategies.
Volume
9
, Issue
4
, April
–
2024
International Journal of Innovative Science and Research Technology
ISSN No:
-
2456
-
2165
https://doi.org/10.38124/ijisrt/IJISRT24APR2251
IJISRT24APR2251
www.ijisrt.com
1183
Given these insights, it is essential to refine c
urrent
diagnostic and treatment protocols to better address the
intricacies of adnexal proliferation in
primary
EMPD.
Conflict of Interest Statement
The authors have no conflicts of interest to declare.
Funding Sources
This study was not supported by any
sponsor or funder.
Author Contributions
All authors have participated sufficiently in the
intellectual content, conception, and design of this
study
. All
authors agree to be accountable for all aspects of the
manuscript.
REFERENCES
[1].
Shaco
-
Levy, R., et al., Paget disease of the vulva: a
study of 56 cases. Eur J Obstet Gynecol Reprod Biol,
2010. 149(1): p. 86
-
91.
[2].
Crocker, H.R., Paget's disease affecting the scrotum
and penis. Trans Pathol Soc Lond, 1889. 40: p. 187
-
191.
[3].
Moretto, P., et al.,
Management of Penoscrotal
Extramammary Paget Disease: Case Series and
Review of the Literature. Current Oncology, 2013.
20(4): p. 311
-
320.
[4].
Scarbrough, C.A., A. Vrable, and D.R. Carr,
Definition, association with malignancy, biologic
behavior, and treatment
of ectopic extramammary
Paget
’
s disease: A review of the literature. The
Journal of clinical and aesthetic dermatology, 2019.
12(8): p. 40.
[5].
Ohara, K., et al., A proposal for a TNM staging
system for extramammary Paget disease:
retrospective analysis of 30
1 patients with invasive
primary tumors. Journal of dermatological science,
2016. 83(3): p. 234
-
239.
[6].
Abbott, J.J. and I. Ahmed, Adenocarcinoma of
mammary
-
like glands of the vulva: report of a case
and review of the literature. The American journal of
derma
topathology, 2006. 28(2): p. 127
-
133.
[7].
Liegl, B., L.
-
C. Horn, and F. Moinfar, Androgen
receptors are frequently expressed in mammary and
extramammary Paget's disease. Modern pathology,
2005. 18(10): p. 1283
-
1288.
[8].
Obaidat, N.A., K.O. Alsaad, and D. Ghazarian
, Skin
adnexal neoplasms
—
part 2: an approach to tumours
of cutaneous sweat glands. Journal of Clinical
Pathology, 2007. 60(2): p. 145
-
159.
[9].
Yin, S., et al., Prevalence of extramammary Paget's
disease in urban China: a population
-
based study.
Orphanet J Rare
Dis, 2021. 16(1): p. 1
-
7.
[10].
Ghazawi, F.M., et al., Demographic and clinical
characteristics of extramammary Paget's disease
patients in Japan from 2000 to 2019. Journal of the
European Academy of Dermatology and
Venereology, 2021. 35(2): p. e133
-
e135.
[11].
Zhang, Z., et al., Cutaneous metastases from triple
primary extramammary Paget's disease. Journal der
Deutschen Dermatologischen Gesellschaft= Journal
of the German Society of Dermatology: JDDG, 2020.
18(10): p. 1169
-
1172.
[12].
Iwamoto, K., et al., Depigmented
extramammary
Paget's disease without histological dermal invasion
identified by multiple inguinal and pelvic lymph
node metastases. European Journal of Dermatology,
2018. 28(3): p. 387
-
388.
[13].
St Claire, K., et al., Extramammary paget disease.
Dermatology onl
ine journal, 2019. 25(4).
[14].
Payapvipapong, K., A. Nakakes, and M. Tanaka,
Lava lake structure and cloud
-
like structureless area:
new clues for diagnosing extramammary Paget
disease. Journal of the European Academy of
Dermatology and Venereology, 2017. 31(10)
: p.
e459
-
e461.
[15].
Mun, J.H., et al., Clinical and dermoscopic
characteristics of extramammary Paget disease: a
study of 35 cases. British Journal of Dermatology,
2016. 174(5): p. 1104
-
1107.
[16].
Regauer, S., Extramammary Paget's disease
—
a
proliferation of adnexal
origin? Histopathology,
2006. 48(6): p. 723
-
729.
[17].
Blanpain, C., et al., Self
-
renewal, multipotency, and
the existence of two cell populations within an
epithelial stem cell niche. Cell, 2004. 118(5): p. 635
-
648.
[18].
Sieber
‐
Blum, M. and M. Grim, The adult hair
follicle: cradle for pluripotent neural crest stem cells.
Birth Defects Research Part C: Embryo Today:
Reviews, 2004. 72(2): p. 162
-
172.
[19].
Tanaka, R., et al., Concordance of the HER2 protein
and gene status between primary and corresponding
lymph node metast
atic sites of extramammary Paget
disease. Clinical & experimental metastasis, 2016.
33: p. 687
-
697.
[20].
Shiomi, T., et al., Extramammary Paget
’
s disease:
evaluation of the adnexal status of 53 cases. Polish
Journal of Pathology, 2015. 66(2): p. 121
-
126.
[21].
Preti,
M., et al., Vulvar Paget's disease and stromal
invasion: clinico
-
pathological features and survival
outcomes. Surgical Oncology, 2021. 38: p. 101581.
[22].
van der Linden, M., et al., Vulvar Paget disease: a
national retrospective cohort study. Journal of the
A
merican Academy of Dermatology, 2019. 81(4): p.
956
-
962.
[23].
Hatta, N., et al., Extramammary Paget
’
s disease:
treatment, prognostic factors and outcome in 76
patients. Br J Dermatol, 2008. 158(2): p. 313
-
318.
[24].
Dai, B., et al., Primary invasive carcinoma associa
ted
with penoscrotal extramammary P aget's disease: a
clinicopathological analysis of 56 cases. BJU
international, 2015. 115(1): p. 153
-
160.
[25].
Ito, T., et al., Tumor thickness as a prognostic factor
in extramammary Paget's disease. The Journal of
Dermatology
, 2015. 42(3): p. 269
-
275.
[26].
Ito, T., Y. Kaku
-
Ito, and M. Furue, The diagnosis and
management of extramammary Paget
’
s disease.
Expert Rev Anticancer Ther, 2018. 18(6): p. 543
-
553.
Volume
9
, Issue
4
, April
–
2024
International Journal of Innovative Science and Research Technology
ISSN No:
-
2456
-
2165
https://doi.org/10.38124/ijisrt/IJISRT24APR2251
IJISRT24APR2251
www.ijisrt.com
1184
[27].
Zhao, Y., et al., Primary extramammary Paget
’
s
disease: a clinicopathological
study of 28 cases. Int J
Clin Exp Pathol, 2019. 12(9): p. 3426.
[28].
Belousova, I.E., et al., Vulvar toker cells: the long
-
awaited missing link: a proposal for an origin
-
based
histogenetic classification of extramammary paget
disease. The American journal of de
rmatopathology,
2006. 28(1): p. 84
-
86.
[29].
Goldblum, J.R. and W.R. Hart, Vulvar Paget's
disease: a clinicopathologic and
immunohistochemical study of 19 cases. The
American journal of surgical pathology, 1997.
21(10): p. 1178
-
1187.
[30].
Hart, W.R. and J.B. Millman,
Progression of
intraepithelial Paget's disease of the vulva to invasive
carcinoma. Cancer, 1977. 40(5): p. 2333
-
2337.
[31].
Konstantinova, A.M., et al., Depth and patterns of
adnexal involvement in primary extramammary
(anogenital) Paget disease: a study of 178
lesions
from 146 patients. Am J Dermatopathol, 2016.
38(11): p. 802
-
808.
[32].
Karam, A., et al., HER
-
2/neu targeting for recurrent
vulvar Paget's disease: a case report and literature
review. Gynecologic oncology, 2008. 111(3): p. 568
-
571.
[33].
Takahagi, S., et al.
, Metastatic extramammary
Paget
’
s disease treated with paclitaxel and
trastuzumab combination chemotherapy. The Journal
of dermatology, 2009. 36(8): p. 457
-
461.
[34].
Delport, E.S., Extramammary Paget's disease of the
vulva: an annotated review of the current li
terature.
Australasian Journal of Dermatology, 2013. 54(1): p.
9
-
21.
[35].
Wollina, U., et al., Surgical treatment for
extramammary Paget
’
s disease. Current treatment
options in oncology, 2018. 19: p. 1
-
12.
[36].
Long, B., et al., A matter of margins: Surgical and
pathologic risk factors for recurrence in
extramammary Paget's disease. Gynecologic
oncology, 2017. 147(2): p. 358
-
363.
[37].
Nabavizadeh, R., et al., Extramammary Paget's
disease: Updates in the workup and man
agement.
Asian Journal of Urology, 2022. 9(4): p. 451
-
459.
[38].
Oashi, K., et al., Combination chemotherapy for
metastatic extramammary Paget disease. British
Journal of Dermatology, 2014. 170(6): p. 1354
-
1357.
[39].
Tanese, K., et al., Updates on the systemic treatm
ent
of advanced non
-
melanoma skin cancer. Frontiers in
medicine, 2019. 6: p. 160.
[40].
Tokuda, Y., F. Arakura, and H. Uhara, Combination
chemotherapy of low
-
dose 5
-
fluorouracil and
cisplatin for advanced extramammary Paget
’
s
disease. International journal of cl
inical oncology,
2015. 20: p. 194
-
197.
Video Explanation for Published paper
close
Cite Paper
MLA
APA
×
Login
Login
Sign Up
Never miss an update from Papermashup
Get notified about the latest tutorials and downloads.
Subscribe by Email
Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR
Subscribe by RSS
Add our RSS to your feedreader to get regular updates from us.
Subscribe